Skip to main content

Table 2 Characteristics of patients escalating vs those not escalating the dose of erenumab during the treatment

From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

CharacteristicEscalating (n = 43)Not escalating (n = 46)P value
Female, n (%)37 (86.0)41 (89.0)0.753
Age, median (IQR)50 (41–56)47 (38–51)0.122
Years of migraine history, median (IQR)30 (20–36)26.5 (18–37)0.436
MMDs, median (IQR)25 (17.5–30)17 (11–25)0.002
Analgesic days, median (IQR)10 (5–28)12 (5–19)0.485
Triptan days, median (IQR)6 (0–20)0 (0–12)0.172
Chronic migraine, n (%)40 (93.0)44 (95.7)0.670
Aura, n (%)12 (27.9)15 (32.6)0.651
Allodynia, n (%)16 (37.2)17 (37.0)0.456
Medication overuse, n (%)35 (81.4)29 (63.0)0.054
Prior preventive treatment failures, n (%)  0.501
 215 (34.9)13 (28.3) 
 > 228 (65.1)33 (71.7) 
Botulinum toxin failure, n (%)22 (51.2)22 (47.8)0.753
\